Lilly Builds On Innovent Biologics Bet
This article was originally published in PharmAsia News
Executive Summary
Lilly has expanded its cancer drug collaboration with Chinese biotech Innovent Biologics with plans to develop and market up to three anti-PD-1 based bi-specific antibodies over the next decade, both inside China's expanding healthcare market and abroad.